STAT+: Inhibrx claims first win for long-sought immunotherapy target
“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.
STAT
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from STAT.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
STAT (www.statnews.com), a Tier B publisher, filed this report on . CurrentWire published this page on .
Signal breakdown
CurrentWire ranked this story 64.5 of 100 in the snapshot this page was rendered from.
- Freshness
- 35 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 8 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 35 of 35. How each signal is calculated.
Filed under Health · International · News.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.